Fat-soluble vitamin existing as phylloquinone (K1, from green plants) and menaquinones (K2, MK-4 to MK-13, from bacterial fermentation and animal tissues). Essential cofactor for γ-glutamyl carboxylase (GGCX), the enzyme that activates vitamin K-dependent proteins (VKDPs) through γ-carboxylation of glutamate residues. This post-translational modification creates calcium-binding sites critical for coagulation, bone mineralization, and vascular protection.
Vitamin K is the postal worker who delivers activation stamps to proteins that need to bind Calcium. Imagine proteins like Osteocalcin (bone builder) and coagulation factors (blood clotters) as letters sitting in the mailbox, unable to do their jobs. They have glutamate residues that are like blank address labels—calcium can't stick to them. Vitamin K (in its reduced, hydroquinone form) is the postal worker who walks up to each letter, stamps a carboxyl group (COO-) onto those glutamate residues, turning them into γ-carboxyglutamate (Gla). Now calcium has a proper binding site—like a zip code—and the protein can do its work.
But here's the catch: every time the postal worker stamps a letter, their ink cartridge oxidizes into vitamin K epoxide—they're out of ink. To keep working, they need the recycling truck (vitamin K epoxide reductase, VKORC1) to come refill their cartridge. Warfarin is the saboteur who slashes the recycling truck's tires—no refill, no stamps, no activated proteins. Meanwhile, K1 mostly handles the coagulation letters in the liver sorting center, while K2 (especially the long-distance MK-7 courier) travels out to bone and blood vessels to activate Osteocalcin and matrix Gla protein (MGP), preventing Calcium from getting misdirected into arterial walls instead of bone.
graph TD
A["Vitamin K Hydroquinone<br/>KH2, Reduced"] -->|GGCX enzyme| B["Vitamin K Epoxide<br/>KO, Oxidized"]
B -->|VKORC1| A
A -->|"γ-carboxylates"| C[Glu residues in VKDPs]
C --> D["Gla residues<br/>γ-carboxyglutamate"]
D -->|Binds| E["Ca²⁺"]
E --> F["Active VKDP<br/>Functional protein"]
G[Warfarin] -.blocks.-> B
style A fill:#90EE90
style B fill:#FFB6C1
style F fill:#87CEEB
style G fill:#FF6B6B
Step-by-step carboxylation:
- Substrate recognition: Vitamin K-dependent proteins (VKDPs) contain a Gla domain with multiple glutamate (Glu) residues, typically in the first 45 amino acids
- Enzyme binding: γ-glutamyl carboxylase (GGCX) recognizes the propeptide region of VKDPs and binds both the substrate and reduced vitamin K (hydroquinone form, KH₂)
- Carboxylation reaction: GGCX adds a carboxyl group (COO⁻) to the γ-carbon of glutamate, creating γ-carboxyglutamate (Gla). This requires CO₂ as the carbon source
- Oxidation: The reaction oxidizes vitamin K hydroquinone → vitamin K epoxide (KO), releasing energy that drives carboxylation
- Recycling: Vitamin K epoxide reductase complex subunit 1 (VKORC1) reduces KO back to vitamin K quinone (K), then vitamin K quinone reductase (or VKORC1 again) reduces K to KH₂—ready for another cycle
- Calcium binding: Gla residues create negatively-charged calcium-binding pockets. Each Gla residue chelates Ca²⁺ through its two carboxyl groups, enabling conformational changes that activate the protein
Key VKDPs and their functions:
-
Coagulation factors (liver-synthesized, K1-dependent):
- Factor II (prothrombin) → thrombin: cleaves fibrinogen to fibrin
- Factor VII: initiates extrinsic pathway
- Factor IX: intrinsic pathway amplification
- Factor X: common pathway, activates prothrombin
- Protein C & Protein S: anticoagulant factors that degrade Va and VIIIa (balance)
-
Bone proteins (extra-hepatic, K2-dependent):
- Osteocalcin (bone Gla protein, BGP): carboxylated form directs Calcium into bone hydroxyapatite; undercarboxylated form (ucOC) is an endocrine hormone regulating insulin sensitivity and testosterone
- Matrix Gla protein (MGP): inhibits vascular calcification by binding Calcium and preventing hydroxyapatite crystal formation in arterial walls; dephospho-uncarboxylated MGP (dp-ucMGP) is a biomarker of K2 deficiency
-
Other VKDPs:
- Growth arrest-specific protein 6 (Gas6): regulates cell survival and inflammation
- Periostin: bone remodeling
- Gla-rich protein (GRP): cartilage calcification inhibitor
- K1 (phylloquinone): Preferentially taken up by liver (70-90% of dietary K1), rapidly used for coagulation factor synthesis, short half-life (~1.5 hours), limited extrahepatic distribution
- K2 (menaquinones): Better lipid solubility → packaged into LDL/VLDL → distributed to extrahepatic tissues (bone, arterial walls, brain, pancreas), longer side-chain MK-7 has half-life ~72 hours vs MK-4 ~1 hour, MK-7 maintains stable blood levels
Vitamin K sits at the crossroads of three selfish systems:
-
Immune system → coagulation cascade: wound healing (Module 5) requires functional coagulation for hemostasis phase. K deficiency → prolonged bleeding → delayed healing. PT/INR monitoring reveals K status (normal PT 11-13.5 seconds; INR 0.8-1.2). Warfarin patients must balance anticoagulation (target INR 2-3 for most conditions) against bleeding risk.
-
Musculoskeletal system → bone metabolism: K2 deficiency is epidemic in modern diets (no fermented foods, industrialized dairy lacking MK-4). Undercarboxylated Osteocalcin (ucOC >4.5 ng/mL suggests K2 deficiency) means Calcium isn't properly directed to bone → osteoporosis despite adequate calcium/Vitamin D intake. The Rotterdam Study showed high K2 intake reduced coronary calcification by 50% and cardiovascular mortality by 57%.
-
Cardiovascular system → vascular calcification prevention: Elevated dp-ucMGP (>500 pmol/L) predicts arterial stiffness and cardiovascular events. K2 carboxylates MGP → active MGP binds calcium phosphate crystals → prevents arterial wall calcification. Warfarin accelerates vascular calcification by blocking this protective mechanism (medial calcification seen within 3-5 years of therapy).
Hunter-gatherers consumed ~10x more K2 than modern populations:
- Fermented foods (natto: 1000 μg MK-7 per 100g)
- Grass-fed animal fats (especially organ meats, marrow)
- Bacterial synthesis in gut (compromised by SIBO, dysbiosis, antibiotic use)
Modern diet provides adequate K1 for minimal coagulation function (~90 μg/day meets AI) but grossly insufficient K2 for optimal bone/vascular health (optimal estimated ~200-500 μg/day MK-7 equivalent).
- Unexplained bruising/bleeding: Check PT/INR, consider K1 deficiency (malabsorption, liver disease, broad-spectrum antibiotics)
- Osteoporosis with normal calcium/D: Measure ucOC ratio (ucOC/total OC >20% = functional K2 deficiency)
- Vascular calcification on imaging: Check dp-ucMGP, supplement K2 (avoid if on warfarin without medical supervision)
- Post-antibiotic therapy: 7-14 day course disrupts K2-producing gut bacteria (Bacteroides, Escherichia coli, Lactobacillus)
Assessment:
- Dietary intake (green vegetables for K1, fermented foods/grass-fed dairy/organ meats for K2)
- Functional biomarkers: ucOC, dp-ucMGP, PT/INR
- Gut health (bacterial K2 synthesis capacity)
- Fat malabsorption conditions (K is fat-soluble: requires bile, pancreatic lipase)
Supplementation thresholds:
- K1: 1 mg/day for coagulation support (bleeding disorders, pre/post-surgery)
- K2 MK-7: 180-360 μg/day for bone/vascular health (most studied dose)
- K2 MK-4: 45 mg/day used in Japanese osteoporosis trials (pharmacological dose)
Contraindications/cautions:
- Warfarin users: stable K1 intake (don't supplement K2 without medical guidance)
- Hypercalcemia: address before adding K2 (will mobilize Calcium to bone)
- Combine with Vitamin D (D increases VKDP synthesis → increases K demand; D+K synergy proven for bone density)
- Metamodel 5 (Wound Healing): K required for coagulation phase; gut dysbiosis impairs K2 production → both bleeding tendency and impaired bone healing
- Selfish Bone System: Bone "steals" calcium from vascular system when K2 is adequate (competitive advantage); K2 deficiency allows vascular system to calcify (lose-lose)
- Evolutionary Medicine: K2 deficiency is a mismatch disease—modern processed food + antibiotic overuse + sedentary lifestyle (reduces bacterial K2 production via altered gut transit time)
- Two dietary forms: K1 (phylloquinone) from green plants; K2 (menaquinones MK-4 to MK-13) from bacterial fermentation and animal conversion
- Adequate Intake (AI): 120 μg/day (men), 90 μg/day (women)—based on coagulation function only, not optimal bone/vascular health
- Half-lives: K1 ~1.5 hours; MK-4 ~1 hour; MK-7 ~72 hours (MK-7 superior for maintaining tissue levels)
- Carboxylation stoichiometry: One vitamin K molecule oxidized per one Gla residue created; typical VKDP has 5-12 Gla residues
- Warfarin mechanism: Blocks VKORC1 at IC50 ~0.2 μM, depleting functional vitamin K pool within 24-48 hours
- Gut bacterial synthesis: Bacteroides fragilis, Escherichia coli, Lactobacillus, Bifidobacterium produce MK-7, MK-8, MK-10, MK-11 (contribute ~10-25% of K2 needs if microbiome healthy)
- ucOC paradox: Undercarboxylated Osteocalcin is a K2 deficiency marker BUT also an active hormone improving insulin sensitivity—dose-dependent U-curve
- Vascular calcification biomarker: dp-ucMGP >500 pmol/L predicts 2-3x cardiovascular event risk
- Natto is the K2 champion: 100g natto contains ~1000 μg MK-7 (vs ~15 μg in hard cheese, ~5 μg in grass-fed butter)
- Critical period: Fetal bone development requires maternal K2; newborns given prophylactic K1 injection (0.5-1 mg IM) to prevent hemorrhagic disease (born with sterile gut, no bacterial K2 synthesis for 3-7 days)
- Osteocalcin — vitamin K2 carboxylates osteocalcin enabling calcium binding to bone; undercarboxylated form (ucOC) is an insulin-sensitizing hormone and testosterone regulator
- Matrix Gla-Protein — K2 carboxylates MGP which inhibits vascular calcification by chelating calcium phosphate in arterial walls; dp-ucMGP is a cardiovascular risk biomarker
- Coagulation cascade — vitamin K1 required for hepatic synthesis of factors II, VII, IX, X and regulatory proteins C & S
- Calcium — Gla residues create high-affinity calcium-binding sites; K2 directs calcium to bone and away from soft tissues
- Vitamin D — increases transcription of VKDPs (osteocalcin, MGP) raising vitamin K requirements; synergistic for bone mineral density
- Vitamin K2 — specific menaquinone forms (MK-4, MK-7) with superior extrahepatic distribution for bone and vascular health
- Warfarin — blocks VKORC1 preventing vitamin K recycling; therapeutic anticoagulation but accelerates vascular calcification and osteoporosis
- Microbiome — gut bacteria synthesize K2 (MK-7 to MK-11); dysbiosis, SIBO, antibiotics impair production
- SIBO — bacterial overgrowth paradoxically reduces K2 bioavailability (wrong species, wrong location, inflammatory gut barrier)
- wound healing — hemostasis phase requires functional coagulation factors; K deficiency prolongs inflammatory phase
- Liver detoxification — hepatocytes synthesize coagulation factors; liver disease impairs both K metabolism and VKDP production
- Vitamin A — regulates osteoblast activity and may compete with K2 for VKORC1; high-dose A supplementation can impair K status
- Vitamin E — high-dose E (>800 IU/day) may antagonize vitamin K function and increase bleeding risk
- Glutamate — substrate for γ-carboxylation; Glu → Gla conversion is the core vitamin K-dependent reaction
- Osteoblasts — synthesize osteocalcin which requires K2 carboxylation to function; regulate bone formation
- insulin sensitivity — undercarboxylated osteocalcin (ucOC) increases adiponectin, enhances pancreatic β-cell proliferation, and improves glucose tolerance
- atherosclerosis — K2 deficiency allows vascular smooth muscle calcification contributing to plaque stability/instability dynamics
- osteoporosis — K2 supplementation (MK-4 45 mg/day or MK-7 180-360 μg/day) reduces fracture risk by 60-80% in trials
- inflammation — Gas6 (vitamin K-dependent) binds TAM receptors (Tyro3, Axl, Mer) on macrophages dampening inflammatory cytokine production
- bile acids — required for K absorption (fat-soluble vitamin); cholestasis or bile acid sequestrants cause K deficiency
- gut bacteria — Bacteroides, E. coli, Lactobacillus produce menaquinones; altered microbiome composition reduces K2 synthesis
- Chronic Kidney Disease — impaired K2 status (uremic toxins inhibit GGCX) contributes to severe vascular calcification; K2 supplementation controversial due to hyperkalemia risk from K-containing foods
- Module 5 (Wound Healing, Bone Healing, Nutrition in Tissue Repair)